Genomill’s vision is to be a leader in the transformation of precision diagnostics with the ultimate goal of enabling the full potential of liquid biopsies across the world.
Genomill is a pioneering precision diagnostics company with a mission to democratize the use of liquid biopsies for oncology, infectious disease detection and beyond, by removing the barriers for global access.
We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our proprietary Geno1® NGS technology platform, enabling significant improvements in costs, performance and scalability.
Our proprietary and patented (US patent nr: 20220298569 and 20220298566) Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation.
It truly provides means for vertical progress and enables fundamental improvements in cost, accuracy, turn-around-time and scalability. It unlocks the future.
We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term collaboration partnerships within oncology and other verticals – infectious diseases, NIPT, antibiotic resistance.
Expert in molecular biology, next-generation DNA sequencing and bioinformatics • Post-doctoral experience at MIT and ETH Zurich • Startup experience at a Harvard Medical School spin-off specializing in single cell transcriptomics
Experienced medtech & life science professional – with several years global experience in commercial functions LATAM, Switzerland, Nordics. • M.Sc Economics Sciences, M.Sc International Politics
MD, PhD in cardiology • International experience in clinical research functions & quality • Big pharma and clinical background
Experienced pediatric pathologist • Pediatric diseases and cancer • 84 scientific publications • Associate Professor
Master of Laws (LL.M) • Several years experience in life science and biotech • Specialities: M&As, startups, IPR
STRATEGIC ADVISOR, BOARD MEMBER
Ex Foundation Medicine, Roche, Genentech executive
Experienced C-level executive, Ex CEO of IDbyDNA
Professor of Human Genomics at University of Tartu • Head of Estonian Biobank Innovation Center • Research Scientist at Broad Institute of MIT and Harvard • Co-author in 350+ scientific publications • Among the 250 most influential scientist in the fields of molecular biology and genetics